Toubib Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.80 M
as on 19-12-2024
- Revenue -24.69%
(FY 2020)
- Profit -29.39%
(FY 2020)
- Ebitda 904.84%
(FY 2020)
- Net Worth 40.41%
(FY 2020)
- Total Assets -51.87%
(FY 2020)
About Toubib Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.80 M.
Sonia and Sansar Chand serve as directors at the Company.
- CIN/LLPIN
U24304CH2017PTC041346
- Company No.
041346
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Toubib Pharma Private Limited offer?
Toubib Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Capsules, Pharmaceutical Syrup, Digestive System Drugs & Medicines, Antacid Drugs, Nutraceuticals & Dietary Supplements, Dietary Supplements, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antibiotic Injection.
Who are the key members and board of directors at Toubib Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sonia  | Director | 16-Jan-2017 | Current |
| Sansar Chand | Director | 21-Mar-2020 | Current |
Financial Performance of Toubib Pharma.
Toubib Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 24.69% decrease. The company also saw a substantial fall in profitability, with a 29.39% decrease in profit. The company's net worth Soared by an impressive increase of 40.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Toubib Pharma?
In 2019, Toubib Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Jul 2021 | ₹0.80 M | Open |
How Many Employees Work at Toubib Pharma?
Unlock and access historical data on people associated with Toubib Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Toubib Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Toubib Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
